Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
19.24
-0.79 (-3.94%)
Jan 17, 2025, 4:00 PM EST - Market closed
Xencor Employees
Xencor had 280 employees as of December 31, 2023. The number of employees decreased by 1 or -0.36% compared to the previous year.
Employees
280
Change (1Y)
-1
Growth (1Y)
-0.36%
Revenue / Employee
$304,157
Profits / Employee
-$708,000
Market Cap
1.35B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
XNCR News
- 7 weeks ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor: Plamotamab NHL Data Leads To RA Program Advancement - Seeking Alpha
- 2 months ago - Xencor Reports Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
- 3 months ago - Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire
- 3 months ago - Xencor Announces Upcoming Change to Board of Directors - Business Wire
- 4 months ago - Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 4 months ago - Xencor: Vudalimab Development Along With Hidden Gem Candidate - Seeking Alpha